UniProtKB/Swiss-Prot Q9Y4W6: Variant p.Tyr605Cys

AFG3-like protein 2
Gene: AFG3L2
Feedback?

Variant information Variant position:

605 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Tyrosine (Y) to Cysteine (C) at position 605 (Y605C, p.Tyr605Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from large size and aromatic (Y) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In OPA12; uncertain significance. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs773240455 [ dbSNP | Ensembl ]

Sequence information Variant position:

605 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

797 The length of the canonical sequence.
Location on the sequence:

LEHADPLLKVSIIPRGKGLG Y AQYLPKEQYLYTKEQLLDRM The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LEHADPLLKVSIIPRGKGLGYAQYLPKEQYLYTKEQLLDRM

Mouse                         LEHADPLLKVSIIPRGKGLGYAQYLPKEQYLYTKEQLLDRM

Bovine                        LEHADPLLKVSIIPRGKGLGYAQYLPREQYLYTREQLLDRM

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	67 – 797	AFG3-like protein 2
Beta strand	605 – 608

Literature citations
ATPase domain AFG3L2 mutations alter OPA1 processing and cause optic neuropathy.
Caporali L.; Magri S.; Legati A.; Del Dotto V.; Tagliavini F.; Balistreri F.; Nasca A.; La Morgia C.; Carbonelli M.; Valentino M.L.; Lamantea E.; Baratta S.; Schoels L.; Schuele R.; Barboni P.; Cascavilla M.L.; Maresca A.; Capristo M.; Ardissone A.; Pareyson D.; Cammarata G.; Melzi L.; Zeviani M.; Peverelli L.; Lamperti C.; Marzoli S.B.; Fang M.; Synofzik M.; Ghezzi D.; Carelli V.; Taroni F.;
Ann. Neurol. 88:18-32(2020)
Cited for: INVOLVEMENT IN OPA12; VARIANTS SPAX5 GLU-306; VAL-462 AND LYS-620; VARIANTS OPA12 PHE-346; SER-377; GLY-407; ILE-430; VAL-462; LYS-465; LEU-514 AND CYS-605; CHARACTERIZATION OF VARIANTS OPA12 GLY-407; VAL-462; LYS-465 AND LEU-514; CHARACTERIZATION OF VARIANT SPAX5 LYS-620;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.